75000 - Document - Document and Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
75010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS
link:presentationLink
link:calculationLink
link:definitionLink
75020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (Parenthetical) (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
75060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
995455 - Disclosure - Description of Operations and Summary of Significant Accounting Policies
link:presentationLink
link:calculationLink
link:definitionLink
995465 - Disclosure - Net Income (Loss) Per Share
link:presentationLink
link:calculationLink
link:definitionLink
995475 - Disclosure - Revenue Recognition
link:presentationLink
link:calculationLink
link:definitionLink
995485 - Disclosure - License and Collaboration Arrangements
link:presentationLink
link:calculationLink
link:definitionLink
995495 - Disclosure - Consolidated Entity
link:presentationLink
link:calculationLink
link:definitionLink
995505 - Disclosure - Equity and Long-Term Investments and Fair Value Measurements
link:presentationLink
link:calculationLink
link:definitionLink
995515 - Disclosure - Goodwill and Intangible Assets
link:presentationLink
link:calculationLink
link:definitionLink
995525 - Disclosure - Balance Sheet Components
link:presentationLink
link:calculationLink
link:definitionLink
995535 - Disclosure - Stock-Based Compensation
link:presentationLink
link:calculationLink
link:definitionLink
995545 - Disclosure - Stockholders' Equity
link:presentationLink
link:calculationLink
link:definitionLink
995555 - Disclosure - Debt
link:presentationLink
link:calculationLink
link:definitionLink
995565 - Disclosure - Commitments and Contingencies
link:presentationLink
link:calculationLink
link:definitionLink
995575 - Disclosure - Asset Acquisition
link:presentationLink
link:calculationLink
link:definitionLink
995585 - Disclosure - Income Taxes
link:presentationLink
link:calculationLink
link:definitionLink
995595 - Disclosure - Segment Reporting
link:presentationLink
link:calculationLink
link:definitionLink
995605 - Disclosure - Description of Operations and Summary of Significant Accounting Policies (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995615 - Disclosure - Net Income (Loss) Per Share (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995625 - Disclosure - Revenue Recognition (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995635 - Disclosure - Consolidated Entity (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995645 - Disclosure - Equity and Long-Term Investments and Fair Value Measurements (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995655 - Disclosure - Goodwill and Intangible Assets (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995665 - Disclosure - Balance Sheet Components (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995675 - Disclosure - Stock-Based Compensation (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995685 - Disclosure - Debt (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995695 - Disclosure - Commitments and Contingencies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995705 - Disclosure - Segment Reporting (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995715 - Disclosure - Description of Operations and Summary of Significant Accounting Policies (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995725 - Disclosure - Net Income (Loss) Per Share - Basic and Diluted EPS (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995735 - Disclosure - Net Income (Loss) Per Share - Anti-Dilutive Securities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995745 - Disclosure - Revenue Recognition - Schedule of net revenue from collaboration arrangement (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995755 - Disclosure - Revenue Recognition - Schedule of net product sales (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995765 - Disclosure - Revenue Recognition (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995775 - Disclosure - License and Collaboration Arrangements (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995775 - Disclosure - License and Collaboration Arrangements (Additional Information) (Details) [Default]
link:presentationLink
link:calculationLink
link:definitionLink
995785 - Disclosure - Consolidated Entity - ISP Fund LP (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995795 - Disclosure - Consolidated Entity - Summary of Individual Investments Held by ISP Fund (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995805 - Disclosure - Equity and Long-Term Investments and Fair Value Measurements - Equity and Other Investments in Armata (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995815 - Disclosure - Equity and Long-Term Investments and Fair Value Measurements - Schedule of Income Statement Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995825 - Disclosure - Equity and Long-Term Investments and Fair Value Measurements - Equity and Other Investments in InCarda (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995835 - Disclosure - Equity and Long-Term Investments and Fair Value Measurements - Equity and Other Investments in ImaginAb (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995845 - Disclosure - Equity and Long-Term Investments and Fair Value Measurements - Equity and Other Investments in Syndeo Biosciences (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995855 - Disclosure - Equity and Long-Term Investments and Fair Value Measurements - Equity Investment in Nanolive (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995865 - Disclosure - Equity and Long-Term Investments and Fair Value Measurements - Convertible Promissory Note in Lyndra (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995875 - Disclosure - Equity and Long-Term Investments and Fair Value Measurements - Equity Investment in Beacon (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995885 - Disclosure - Equity and Long-Term Investments and Fair Value Measurements - Reconciliation of Equity and Long-Term Investments Balances (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995895 - Disclosure - Equity and Long-Term Investments and Fair Value Measurements - Available-for-Sale Securities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995905 - Disclosure - Equity and Long-Term Investments and Fair Value Measurements - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995915 - Disclosure - Equity and Long-Term Investments and Fair Value Measurements - (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995925 - Disclosure - Goodwill and Intangible Assets (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995935 - Disclosure - Goodwill and Intangible Assets - Summary of Accumulated Amortization of Recognized Intangible Assets (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995945 - Disclosure - Balance Sheet Components - Schedule of Inventory (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995955 - Disclosure - Balance Sheet Components (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995965 - Disclosure - Balance Sheet Components - Schedule of Other Accrued Liabilities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995975 - Disclosure - Balance Sheet Components - Schedule of Other Long-term Liabilities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995985 - Disclosure - Stock-Based Compensation (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995995 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995995 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details) [Default]
link:presentationLink
link:calculationLink
link:definitionLink
996005 - Disclosure - Stockholders' Equity (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996015 - Disclosure - Debt - Schedule of Debt (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996025 - Disclosure - Debt - Schedule of Debt (Details) 2
link:presentationLink
link:calculationLink
link:definitionLink
996035 - Disclosure - Debt - Convertible Senior Notes (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996045 - Disclosure - Debt - Convertible Senior Notes (Details) 2
link:presentationLink
link:calculationLink
link:definitionLink
996055 - Disclosure - Debt - Debt Maturities (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996065 - Disclosure - Commitments and Contingencies (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996075 - Disclosure - Commitments and Contingencies - Schedule of Components of Lease Cost (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996085 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996095 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996105 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details) 2
link:presentationLink
link:calculationLink
link:definitionLink
996115 - Disclosure - Asset Acquisition (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996125 - Disclosure - Income Taxes - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996135 - Disclosure - Segment Reporting (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996145 - Disclosure - Segment Reporting - Schedule of Reconciliation to the Consolidated Net Income (Details)
link:presentationLink
link:calculationLink
link:definitionLink
Purchase Obligation, to be Paid, Year Two
Future minimum purchase commitments, 2027
Balance Sheet Related Disclosures [Abstract]
Gross Profit
Gross profit
Gross profit
Common Stock, Capital Shares Reserved for Future Issuance
Common stock, capital shares reserved for future issuance
Royalty rate for sales above first level of annual global net sales (as a percent)
Collaborative Arrangement, Royalty Rate Defined, Level Two
Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales.
Schedule of Other Accrued Liabilities
Schedule of Accrued Liabilities [Table Text Block]
Preferred stock, shares issued
Preferred Stock, Shares Issued
Preferred Stock, Shares Issued, Total
Debt
Debt Disclosure [Text Block]
Operating Lease, Liability
Total operating lease liabilities
Total operating lease liabilities
Interest expense
Interest Expense, Operating and Nonoperating
Interest Expense, Total
Interest expense
Interest expense
Debt, Long-Term and Short-Term, Combined Amount
Total debt, net
Net carrying amount
Over-Allotment Option [Member]
Over-Allotment Option
Current Portion Of ISP Fund Investments
Current portion of ISP Fund investments
Current portion of ISP Fund investments
Commitments and contingencies (Note 12)
Commitments and Contingencies
Weighted Average Number of Shares Outstanding, Diluted
Diluted
Weighted-average shares used to compute diluted net income (loss) per share
Asset Acquisition [Axis]
APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total
Stock-based compensation
Lessee, Operating Lease, Term of Contract
Lease term
Minimum [Member]
Minimum
Long-Term Debt, Maturity, Year Two
2028
Private Placement [Member]
Private Placement
Debt Instrument, Interest Rate, Effective Percentage
Effective interest rate
Debt Instrument, Interest Rate, Effective Percentage
Preferred stock, shares outstanding
Preferred Stock, Shares Outstanding
Preferred Stock, Shares Outstanding, Beginning Balance
Preferred Stock, Shares Outstanding, Ending Balance
Investment, Name [Axis]
Equity method investments
Equity Method Investment
Equity method investment.
Customer two.
Customer Two [Member]
Customer Two
Recurring basis
Fair Value, Recurring [Member]
Net Investment Related Income Expenses Earned Inccured
Net investment related income expenses earned inccured.
Net investment-related income (expense) earned (incurred)
Reconciliation of Equity and Long-Term Investments Balances
Schedule of reconciliation of equity and long-term investments balance.
Schedule of Reconciliation of Equity and Long-Term Investments Balance [Table Text Block]
Consolidated Entities [Domain]
Consolidated Entities [Domain]
Preferred stock
Investments in Preferred Stock
Investments in preferred stock.
Common stock, shares issued
Common Stock, Shares, Issued
Common Stock, Shares, Issued, Total
Segment Reporting [Line Items]
Inventory fair value step-up adjustment included in cost of products sold
Inventory Fair Value Step Up Adjustment Included In Cost Of Product Sales
Inventory fair value step-up adjustment included in cost of product sales.
Equity and long-term investments at carrying value
Carrying Amount of Investment
Carrying amount of investment
Debt Instrument, Face Amount
Loan amount
Convertible notes face value
Aggregate principal amount
Income tax expense, net
Income Tax Expense (Benefit)
Income tax benefit (expense), net
Income tax benefit (expense), net
Income tax expense (benefit), net
Syndeio 2025 Convertible Note
Syndeio Two Thousand Twenty Five Convertible Note [Member]
Syndeio two thousand twenty five convertible note.
Property, Plant and Equipment [Member]
Property and equipment
InCarda October Two Thousand Twenty Five Convertible Note [Member]
InCarda October Two Thousand Twenty Five Convertible Note [Member]
InCarda October 2025 Convertible Note
Counterparty Name [Domain]
Counterparty Name [Domain]
Cash Distributions
Cash distributions.
Cash distribution
Deferred Royalty Obligations
Deferred royalty obligations.
Deferred Royalty obligations
Operating Segments
Operating Segments [Member]
Intangible Asset, Finite-Lived, Class [Domain]
Net Income (Loss) Per Share [Abstract]
No definition available.
Net income (loss) per share
Stock Issued During Period, Value, Conversion of Convertible Securities
Conversion of 2025 Notes to common stock
Health care royalty partners member.
Health Care Royalty Partners [Member]
HealthCare Royalty Partners
Aggregate principal amount
Line of Credit Facility, Maximum Borrowing Capacity
Common stock and warrants
Common Stock And Warrants [Member]
Represents information pertaining to common stock and warrants.
Stock-based compensation (in shares)
Adjustments to additional paid in capital share based compensation requisite service period recognition shares.
Adjustments To Additional Paid In Capital Share based Compensation Requisite Service Period Recognition Shares
Accrued Income Taxes, Current
Income tax payable
Amortized Cost
Debt Securities, Available-for-Sale, Amortized Cost
Subsequent Event Type [Domain]
Work-in-process
Inventory, Work in Process, Net of Reserves
Description of Operations
Description of Operations [Policy Text Block]
Description of operations.
Cost of Goods and Services Sold, Total
Cost of Product and Service Sold
Cost of products sold
Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding amortization of intangible assets)
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]
Debt
Debt [Member]
Less: imputed interest
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Less: imputed interest
Intangible Asset, Finite-Lived, Acquired, Residual Value
Useful life of Remaining In Process Research and Development
Royalty agreement, maximum potential payout, percent.
Royalty Agreement Maximum Potential Payout Percent
Maximum potential royalty payout
Geographic Concentration Risk
Geographic Concentration Risk [Member]
Represents information pertaining to Burlingame, California.
Burlingame California [Member]
Burlingame, California
Schedule of Components of Interest Expense
Interest Income and Interest Expense Disclosure [Table Text Block]
AstraZeneca.
AstraZeneca [Member]
Astrazeneca
Payments to Acquire Long-Term Investments
Additional cash investment
Schedule of Long-Term Debt Instruments [Table]
Reclassification of Current Portion
Reclassification of current portion.
Reclassification of current portion
General and administrative
General and Administrative Expense
General and Administrative Expense, Total
Income Statement [Abstract]
Lease, Cost [Table Text Block]
Schedule of Components of Lease Cost
Proceeds from trading securities
Proceeds from Sale of Securities, Operating Activities
Related Party [Domain]
Related and Nonrelated Parties [Domain]
Intangible Asset, Finite-Lived [Table]
Earnings Per Share, Basic
Earnings Per Share, Basic, Total
Basic
Basic
Amortization of Acquired Intangible Assets
Amortization of acquired intangible assets.
Amortization of acquired intangible assets
Upfront Fee
Upfront fee.
Upfront fee
Document Period End Date
Intangible Asset, Finite-Lived, Estimated Amortization Expense, Remainder of Fiscal Year
Future amortization expense, remainder of 2026
Series B2 Preferred Stock [Member]
Series B2 Preferred Stock.
Series B-2 Preferred Stock [Member]
Series B preferred stock
Series B Preferred Stock [Member]
Payments to Acquire Property, Plant, and Equipment
Payments to Acquire Property, Plant, and Equipment, Total
Purchases of property and equipment
Debt
Debt Instrument [Line Items]
Regulatory Milestone Achievement
Regulatory Milestone Achievement [Member]
Regulatory milestone achievement.
Common stock, shares authorized
Common Stock, Shares Authorized
Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Two
Future amortization expense, 2028
Statement of Stockholders' Equity [Abstract]
Prepaid expenses
Prepaid Expense and Other Assets, Current
Income Statement Related Disclosures [Abstract]
Income Statement Information
Changes in fair values of equity method investments, net
Changes in fair values of equity method investments, net
Income (Loss) from Equity Method Investments
Increase (Decrease) in Income Taxes Payable
Income tax payable
Everest Medicines Limited [Member]
Everest Medicines Limited [Member]
Everest Medicines Limited
Purchase Obligation, to be Paid, Year One
Future minimum purchase commitments, 2026
Waltham Massachusetts Member
Waltham Massachusetts Member
Waltham Massachusetts Member
Investments [Domain]
Investments [Domain]
Capitalized Contract Cost, Net, Noncurrent
Capitalized cost of fixed assets
Upfront Cash Payments
Upfront cash payments.
Upfront cash payment
Massachusetts Institute of Technology [Member]
Massachusetts institute of technology.
Massachusetts Institute of Technology
Debt Instrument, annual interest rate
Debt Instrument, Interest Rate, Stated Percentage
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Disaggregation of Revenue [Table]
Total assets
Total assets
Assets
Title of 12(b) Security
Goodwill
Goodwill, Total
Goodwill
Balance as of December 31, 2021
Balance as of March 31, 2022
Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding
Preferred Stock, Value, Issued
Preferred Stock, Value, Issued, Total
Preferred Stock, Value, Issued, Beginning Balance
Preferred Stock, Value, Issued, Ending Balance
Preferred stock
Repayments of Short-Term Debt
Repayments of Short-Term Debt, Total
Repayments of notes
Repurchase of common stock
Repurchase of common stock
Payments for Repurchase of Common Stock
Development Regulatory and Sales Milestone [Member]
Development regulatory and sales milestone.
Development, Regulatory and Sales Milestone
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Schedule of Stock-Based Compensation Expense
The number of the Company's Board members currently serving on the Investee's Board.
Number of the Company's Board Members Currently Serving on the Board of Investee
Number of Investee's Board members currently representing the Company
Customer Concentration Risk [Member]
Customer Concentration Risk
Cash paid for amounts included in the measurement of operating lease liabilities
Operating Lease, Payments
Antidilutive Securities, Name [Domain]
Antidilutive Securities, Name [Domain]
2025 Notes converted to common stock
Stock Issued
Effective tax rate (as a percent)
Effective Income Tax Rate Reconciliation, Percent
Effective Income Tax Rate Reconciliation, Percent, Total
Commercial supply agreement.
Commercial Supply Agreement [Member]
Commercial Supply Agreement
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year
Remainder of 2026
Cash paid for interest
Interest Paid, Excluding Capitalized Interest, Operating Activity
Product
Product [Member]
Net product sales
Convertible subordinated notes
Convertible Subordinated Debt [Member]
Goodwill [Line Items]
Total gross carrying amount
Intangible Asset, Excluding Goodwill, before Accumulated Amortization
Total gross carrying amount
Lessee, Operating Lease, Liability, to be Paid, Year One
2027
Location, Statement of Financial Position, Balance [Axis]
Percentage of reimbursed for direct and certain indirect manufacturing costs.
Percentage Of Reimbursed For Direct And Certain Indirect Manufacturing Costs
Percentage of reimbursed for direct and certain indirect manufacturing costs
RELVAR/BREO
Long Acting Beta2 Agonist Relvar Breo [Member]
Represents Long-Acting Beta2 Agonist, RELVAR/BREO, which is being developed and commercialized by entering into a strategic alliance with GSK
Class of Treasury Stock [Table]
Disaggregation of Revenue [Table Text Block]
Schedule of net revenue from collaboration arrangement
External Services and Expenses [Member]
External services and expenses.
External Services and Expenses
Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Four
Future amortization expense, 2030
Equity, Attributable to Parent
Equity, Attributable to Parent, Ending Balance
Equity, Attributable to Parent, Beginning Balance
Total stockholders' equity
Accrued interest payable
Increase (Decrease) in Interest Payable, Net
Treasury Stock
Treasury Stock, Common [Member]
Other assets
Other Assets, Noncurrent
Other Assets, Noncurrent, Total
Arrangements and Non-arrangement Transactions [Domain]
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Income Taxes
Income Tax Disclosure [Text Block]
Royalty Payments
Royalty Payments
Royalty Payments
Upfront Payment Under Intangible Asset
Upfront payment under intangible asset.
Upfront payment under intangible asset
Armata May Two Thousand Twenty Six Term Loan [Member]
Armata may two thousand twenty six term loan.
Armata May 2026 Term Loan
Convertible Notes [Member]
Convertible notes member.
Convertible Notes
Earnings Per Share [Text Block]
Net Income Per Share
Net Income (Loss) Per Share
Accrued contract manufacturing liability.
Accrued Contract Manufacturing Liability
Accrued contract manufacturing expenses
Number of Reportable Segments
Number of Reportable Segments
Revenue Benchmark [Member]
Net Product Sales
Asset Acquisition [Text Block]
Asset Acquisition
Basis of Presentation
Basis of Accounting, Policy [Policy Text Block]
Armata convertible note member.
Armata Convertible Note
Gross Unrealized Gains
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Investment [Table Text Block]
Summary of Individual Investments Held by ISP Fund
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
Dilutive effect of outstanding warrant
Geographical [Domain]
Annual global sales level used to determine royalty rate
Collaborative Arrangement, Specified Sales Level for Determining Royalty Rate
Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement.
Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Three
Future amortization expense, 2029
Equity method investments at fair value
Fair value of equity securities
Equity and long-term investments at fair value
Aggregate Scheduled Maturities of Convertible Debt
Schedule of Maturities of Long-Term Debt [Table Text Block]
Statistical Measurement [Axis]
Lease space
Area of Real Estate Property
Money market funds
Money Market Funds [Member]
Entity Interactive Data Current
Convertible Debt, Fair Value Disclosures
2028 Notes
Lessee, Operating Lease, Liability, to be Paid, Year Three
2029
Accrued Interest Income Included in Long-term Investments
Accrued interest income included in long-term investments.
Accrued interest income converted to long-term investments
Goodwill [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common Stock, Value, Issued
Common Stock, Value, Issued, Total
Common Stock, Value, Issued, Beginning Balance
Common Stock, Value, Issued, Ending Balance
Common stock
Common stock: $0.01 par value, 200,000 shares authorized, 72,637 and 74,636 issued and outstanding as of June 30, 2026 and December 31,2025, respectively
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Schedule of computation of basic and diluted net income (loss) per share
Inventory [Line Items]
Marketed products
Marketed products.
Marketed Products [Member]
Royalty expense
Royalty Expense
Proceeds from Sale of Property, Plant, and Equipment, Total
Proceeds from Sale of Property, Plant, and Equipment
Sale of property and equipment
Total liabilities
Liabilities, Total
Liabilities
Net Sales and Purchases of Investments Managed by ISP Fund
Net Sales and Purchases of Investments Managed by ISP Fund
Net sales and purchases of investments managed by ISP Fund
InCarda February TwoThousand Twenty Five Convertible Note [Member]
InCarda February TwoThousand Twenty Five Convertible Note [Member]
InCarda February 2025 Convertible Note
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total
Less: Unamortized debt discount and issuance costs
Debt issuance costs, net
Debt discount and issuance costs, net
Collaborative Arrangement [Member]
Collaboration agreement
XERAVA
XERAVA.
XERAVA [Member]
XERAVA [Member]
License and collaboration arrangements disclosure.
License and Collaboration Arrangements Disclosure [Text Block]
License and Collaboration Arrangements
Other non-cash items
Other Noncash Income (Expense)
Other Noncash Income (Expense), Total
Interest on Convertible Debt, Net of Tax
Add: interest expense on Notes, net of tax effect
Product and Service [Axis]
Long-Acting Beta2 Agonist (LABA) Collaboration
Laba Collaboration [Member]
Represents the collaboration with GSK to develop and commercialize once-daily LABA products and combination products RELVAR.
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Retained Earnings (Accumulated Deficit), Total
Retained Earnings (Accumulated Deficit), Beginning Balance
Retained Earnings (Accumulated Deficit), Ending Balance
Retained earnings
Call Option [Member]
Stock prices below $27.79 per share
Stock prices below $26.22 per share
Significant Unobservable Inputs, Level 3
Fair Value, Inputs, Level 3 [Member]
Asset Acquisitions [Policy Text Block]
Disclosure of accounting policy for asset acquisitions.
Asset Acquisitions
Accounts payable
Increase (Decrease) in Accounts Payable
Increase (Decrease) in Accounts Payable, Total
Equity investment ownership percentage
Equity Method Investment, Ownership Percentage
Equity method investment ownership percentage
Operating Expenses
Total operating expenses
Total operating expenses
Fair Value, by Balance Sheet Grouping [Table]
Disaggregation of Revenue [Line Items]
Revenue Recognition and Collaboration Arrangements
Changes in operating assets and liabilities:
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]
Interim Supply Agreement
Interim supply agreement member.
Interim Supply Agreement [Member]
Number of Warrants Owned
Number of warrants owned.
Number of warrants owned
Number of shares issued
Stock Issued During Period, Shares, New Issues
Increase (Decrease) in Prepaid Expense
Prepaid expenses
Prepaid expenses
Lease, Cost [Abstract]
Accrued excise tax on common stock repurchase applied against tax liability, shares
Accrued Excise Tax On Common Stock Repurchase Applied Against Tax Liability Shares
Accrued excise tax on common stock repurchase applied against tax liability shares.
Lyndra
Lyndra [Member]
Lyndra.
Deferred Income Tax Liabilities, Net
Deferred tax liabilities, net
Innoviva TRC Holdings, LLC [Member]
Innoviva TRC Holdings, LLC.
Innovia TRC Holdings , LLC
Armata
Armata Pharmaceuticals Inc [Member]
Represents information pertaining to Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections.
Accumulated amortization
Intangible Asset, Finite-Lived, Accumulated Amortization
Accumulated amortization
Accumulated amortization
Represents information pertaining to equity investments and money market funds.
Equity Investments And Money Market Funds [Member]
Equity investments and Money market funds
Privately Held Healthcare Companies
Privately held healthcare companies.
Privately Held Healthcare Companies [Member]
Subscription agreement one-time milestone payment on commercial sales.
Subscription Agreement One-time Milestone Payment on Commercial Sales
One-time milestone payment on commercial sales
Accounting Standards Update 2020-06 [Member]
ASU 2020-06
ASU 2020-06
Operating Lease, Cost
Straight line operating lease costs
Credit and Security Agreement [Member]
Credit and security agreement.
Credit and Security Agreement [Member]
Changes in fair values of equity and long-term investments income, net
Unrealized gain from fair value changes in equity investments
Equity Securities, FV-NI, Unrealized Gain
Unrealized gain
Other Income
Other
Fair Value Hierarchy and NAV [Axis]
Short-Term Debt, Type [Axis]
Assets
Assets, Fair Value Disclosure [Abstract]
The total number of Board members of the Investee.
Number of Board Members of the Investee
Number of the Investee's Board members
Inventory, Current [Table]
Intangible Asset, Indefinite-Lived, Class [Axis]
Asset Acquisition [Table]
Convertible Promissory Note [Member]
Convertible promissory note member.
Convertible Promissory Note
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]
Estimated Fair Value
Debt Securities, Available-for-Sale
Debt Securities, Available-for-Sale, Total
Gain (Loss) on Other Investments
Gain loss on other investments.
Changes in fair values of equity and long-term investments, net
Changes in fair values of equity and long-term investments, net
Changes in fair value, net
Operating Lease, Liability, Current
Current portion of lease liabilities
Current portion of lease liabilities
Option Indexed to Issuer's Equity, Type [Domain]
Concentration Risk Type [Domain]
Customer [Domain]
Debt Instrument, Convertible, Conversion Ratio
Conversion rate for shares of common stock per $1,000 principal
Total liabilities and stockholders' equity
Liabilities and Equity
Amended Zai Agreement.
Amended Zai Agreement [Member]
Amended Zai Agreement
Lessee, Operating Lease, Liability, to be Paid, Year Two
2028
Research and Development Expense
Research and Development Expense, Total
Research and development
Research and development expense
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Table Text Block]
Schedule of net product sales
Upfront Fee Payment
Upfront fee payment.
Upfront fee payment
Intangible Asset, Finite-Lived, Class [Axis]
Lessee, Lease, Description [Table]
Document Fiscal Period Focus
Schedule of Supplemental Cash Flow Information Related to Leases
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]
Proceeds from (Payments for) Trading Securities, Short-Term
Proceeds from trading securities
Privately-negotiated capped call option
Privately Negotiated Capped Call Option [Member]
Represents the capped call option entered in connection with the offering of convertible debt.
Entasis Therapeutics Holdings Inc [Member]
Represents information pertaining to Entasis Therapeutics Holdings Inc.
Entasis
Schedule of Inventory, Current [Table Text Block]
Schedule of Inventory
Corden Pharma.
Corden Pharma [Member]
Corden Pharma [Member]
Development, Regulatory and Royalty [Member]
Development, regulatory and royalty.
Development, Regulatory and Royalty
Accrued professional services
Accrued Professional Services
Accrued Professional Services
Accrued Royalties, Current
Royalty obligation payable
Sale of Stock [Axis]
Purchase Obligation, to be Paid, Remainder of Fiscal Year
Future minimum purchase commitments, remainder of 2025
Intangible Asset, Finite-Lived, Useful Life
Estimated useful life
Marketed products, Useful Life
Durlobactam
Durlobactam [Member]
Durlobactam.
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Net increase in cash and cash equivalents
Entity Current Reporting Status
Current portion of deferred royalty obligations
Deferred Royalty Obligation, Current
Current portion of deferred royalty obligation.
Use of Management's Estimates
Use of Estimates, Policy [Policy Text Block]
Dr. Reddy's Laboratories
Dr Reddys Laboratories [Member]
Dr Reddys Laboratories.
Quoted Price in Active Markets for Identical Assets, Level 1
Fair Value, Inputs, Level 1 [Member]
Class of Stock [Domain]
Accounts payable
Accounts Payable, Current
Accounts Payable, Current, Total
Syndeio Biosciences [Member]
Syndeio Biosciences.
Syndeio Biosciences [Member]
Realized Investment Gains (Losses)
Realized gain (loss) on equity investments
Investment Type [Axis]
Schedule of anti-dilutive securities
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Financial Instrument [Axis]
Assets, Fair Value Disclosure, Total
Total assets measured at estimated fair value
Assets, Fair Value Disclosure
Document Transition Report
Commitments and Contingencies Disclosure [Abstract]
Increase (Decrease) in Inventories, Total
Increase (Decrease) in Inventories
Inventory
Syndeio Two Thousand Twenty One Convertible Note [Member]
Syndeio two thousand twenty one convertible note.
Syndeio 2021 Convertible Note
Accounting Standards Update [Domain]
Amount of investment in preferred stock
Amount Of Investments In Preferred Stock
Amount of investments in preferred stock.
Receivables, Long-Term Contracts or Programs
Receivable from collaboration arrangement
Current liabilities:
Liabilities, Current [Abstract]
Share-Based Payment Arrangement [Abstract]
Research and Development Support [Member]
Research and Development Support [Member]
Research and Development Support
Asset Acquisition, Consideration Transferred, Transaction Cost
Direct transaction costs
Common stock
Common Stock [Member]
Common Stock [Member]
Inventory, Finished Goods, Net of Reserves
Finished goods
Net Income Per Share
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]
Accounting Standards Update [Axis]
Range [Domain]
Statistical Measurement [Domain]
Total royalties
Gross Revenue from Contract with Customer, Excluding Assessed Tax, Before Amortization Of Capitalized Fees
Gross Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer before amortization of capitalized fees.
Royalties
Total royalties
Available-for-Sale Securities
Debt Securities, Available-for-Sale [Line Items]
Stockholders' equity:
Equity, Attributable to Parent [Abstract]
Weighted Average Number of Shares Outstanding, Basic
Weighted Average Number of Shares Outstanding, Basic, Total
Basic
Weighted-average shares used to compute basic net income (loss) per share
Equity Incentive Plans And E S P P [Member]
Represents information pertaining to options, Equity Incentive Plans and Employee Stock Purchase Plans.
Equity incentive plans and ESPP
Assets [Abstract]
Assets
Entity Central Index Key
Antidilutive Securities [Axis]
Consolidation Items [Axis]
Current Fiscal Year End Date
Increase (Decrease) in Accrued Liabilities, Total
Accrued personnel-related expenses and other accrued liabilities
Increase (Decrease) in Accrued Liabilities
Document Quarterly Report
Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table]
Debt Instrument, Maturity Date
Debt instrument maturity date
Debt instrument maturity date
Term loan investment
Term Loan Investment [Member]
Term loan investment.
Net Income (Loss) Available to Common Stockholders, Diluted
Net income (loss), diluted
Debt Securities, Available-for-Sale [Table]
Common stock - Publicly traded healthcare companies
Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]
Lease Expiration Date
Lease expiration, date
Long-Term Debt, Maturity, Remainder of Fiscal Year
Remainder of 2026
Accrued license fees and royalties
Accrued License Fees and Royalties
Accrued license fees and royalties
Significant Other Observable Inputs, Level 2
Fair Value, Inputs, Level 2 [Member]
Unrealized Gain (Loss) on Investments
Changes in fair values of equity and long-term investments, net
Unrealized gain (loss) on other equity investments
Principal
Total debt
Debt Instrument Principal Amount
Debt Instrument Principal Amount
Net cash provided by operating activities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Entity Incorporation, State or Country Code
Earnings Per Share, Diluted
Earnings Per Share, Diluted, Total
Diluted
Net income per share: diluted
Preferred stock, par value (in dollars per share)
Preferred Stock, Par or Stated Value Per Share
Operating Lease, Weighted Average Discount Rate, Percent
Operating Lease, Weighted Average Discount Rate, Percent
Option Indexed to Issuer's Equity, Type [Axis]
Exercise of stock options and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding
Exercise of stock options and issuance of common stock units, stock awards and purchase plan, net of cancellation of stock awards and repurchase of shares for tax withholding
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total
Other assets
Increase (Decrease) in Other Operating Assets
Increase (Decrease) in Other Operating Assets, Total
Commitments and Contingencies
Commitments and Contingencies Disclosure [Text Block]
GARDP Collaboration Agreement [Member]
GARDP collaboration agreement.
GARDP Collaboration Agreement
Sales of equity investments managed by ISP Fund LP
Sale of equity investments managed by ISP FUND LP
Sale of equity investments managed by ISP FUND LP
Date of acquisition agreement
Asset Acquisition, Date of Acquisition Agreement
Payments for Purchase of Securities, Operating Activities
Purchases of trading securities
Goodwill and Intangible Assets, Policy [Policy Text Block]
Goodwill and Intangible Assets
Supplemental Balance Sheet Disclosures [Text Block]
Balance Sheet Components
Lease Contractual Term [Domain]
Debt Conversion, Converted Instrument, Shares Issued
Principal amount converted in to shares
Variable Interest Entity
Variable Interest Entity, Primary Beneficiary [Member]
Principal Amount of Convertible Notes Owned
Principal amount of convertible notes owned.
Principal amount of convertible notes owned
Changes in fair values of equity and long-term investments expense, net
Unrealized loss
Equity Securities, FV-NI, Unrealized Loss
Unrealized loss from fair value changes in equity investments
Fair Value, Measurement Frequency [Domain]
Measurement Frequency [Domain]
Rule 10b51 Arr Modified Flag
Rule 10b51 Arr Modified Flag.
Rule 10b51Arrangement Modified
Equity Components [Axis]
Royalty agreement increase in maximum potential payout percent.
Royalty Agreement Increase In Maximum Potential Payout Percent
Increase in maximum potential payout percent
Cash flows from investing activities
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]
Gain (Loss) on Investments
Net realized and unrealized gain (loss) on equity investments
Net fair value adjustment of inventory from acquisition
Value of net fair value adjustment of inventory resulting from the acquisition.
Fair Value Adjustments Of Inventory From Acquistion
Cash paid for in-process research and development assets acquired
Payments to Acquire in Process Research and Development
Percentage of Economic Interest In Partnership
Percentage of economic interest held in Partnership.
Economic interest of the partnership (in percent)
Statement of Cash Flows [Abstract]
Fair Value Hierarchy [Domain]
Fair Value Hierarchy and NAV [Domain]
Income Tax Disclosure [Abstract]
ZEVTERA [Member]
ZEVTERA.
ZEVTERA [Member]
Consolidated Entity [Text Block]
The entire disclosure for consolidated entity.
Consolidated Entity
Revenue Recognition
Revenue [Policy Text Block]
Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
Incremental Common Shares Attributable to Conversion of Debt Securities, Total
Dilutive effect
Equity Securities Owned Percentage
Equity securities owned percentage.
Equity investment ownership percentage
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]
Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis
Net Carrying Amount
Intangible assets
Net carrying amount
Net carrying amount
InCarda 2024 Convertible Note
InCarda Two Thousand Twenty Four Convertible Note [Member]
InCarda two thousand twenty four convertible note.
Financial Instruments Disclosure [Text Block]
Equity and Long-Term Investments and Fair Value Measurements
2025 Notes
Convertible Senior Debt, Fair Value Disclosures
Fair value portion of long-term notes which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. Senior debt has the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment.
Purchase Of Equity And Other Long Term Investments
Purchase of equity and other long term investments.
Purchases of equity and other long-term investments
Purchases of equity and other long-term investments
Investments [Abstract]
Common stock - Publicly traded healthcare companies
Equity and long-term investments
Long-Term Investments
Long-term Investments, Total
Equity and long-term investments
Equity and long-term investments
Preferred stock, shares authorized
Preferred Stock, Shares Authorized
Loans Payable [Member]
Loans Payable
Lyndra Convertible Note
Lyndra Convertible Note [Member]
Lyndra convertible note.
Class of Stock [Axis]
Anti-dilutive securities (in shares)
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Counterparty Name [Axis]
Asset Acquisition [Line Items]
Accrued clinical and research liability.
Accrued Clinical and Research Liability
Accrued clinical and research expenses
GIAPREZA
GIAPREZA.
GIAPREZA [Member]
GIAPREZA [Member]
Number of Operating Segments
Number of Operating Segments
Increase (Decrease) in Deferred Revenue
Deferred revenue
Inventory, Net
Inventory
Total inventory
Purchase and sale of other investments managed by ISP FUND LP
Purchase and sales of other investments managed by ISP Fund LP, net
Purchases and sales of other investments managed by ISP Fund LP, net
Purchase and sale of other investments managed by ISP FUND LP, net
Variable Interest Entities
Consolidation, Variable Interest Entity, Policy [Policy Text Block]
Segment Reporting
Segment Reporting, Policy [Policy Text Block]
Non-US [Member]
Rest of the world
Non-US
Concentration Risk Benchmark [Domain]
Conversion price of convertible notes into common stock (in dollars per share)
Debt Instrument, Convertible, Conversion Price
Conversion price (dollars per share)
Beacon [Member]
Beacon [Member]
Stock-based compensation
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Term of milestone payment for net sales.
Term of Milestone Payment for Net Sales
Term of the milestone payment on net sales
Customer [Axis]
Gross Unrealized Losses
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Intangible Asset, Goodwill and Other [Abstract]
Research and Development Expenses
Research and Development Expense, Policy [Policy Text Block]
Document Type
ISP Fund LP
Isp Fund Lp [Member]
Represents information pertaining to ISP Fund LP, an investment managed by Sarissa Capital.
Convertible Debt [Member]
Convertible debt investment
Convertible debt investment
Cash flows from operating activities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]
Liabilities and LLC Members' Equity
Liabilities and Stockholders' Equity
Liabilities and Equity [Abstract]
Lessee, Lease, Description [Line Items]
Subsequent Event
Subsequent Event [Member]
Operating Income (Loss)
Loss from operations
Loss from operations
Income from operations
Internal Expenses [Member]
Internal Expenses.
Internal expenses
PAION AG [Member]
PAION AG [Member]
PAION AG
Zoliflodacin
Zoliflodacin [Member]
Zoliflodacin.
Equity Securities, FV-NI, Realized Gain
Realized gain from fair value changes in equity investments
Represents the royalty payable as a percentage of payments received from sublicensees.
Percentage Of Royalty On Payments Received From Sublicensees
Percentage of royalty on payments received from sublicensees
Segment Reporting [Table]
Selling and Marketing Expense
Selling and Marketing Expense, Total
Selling and marketing
Lessee, Operating Lease, Existence of Option to Terminate [true false]
Asset Class [Domain]
Securities Act File Number
Revenue from Contract with Customer [Text Block]
Revenue Recognition
Accrued Liabilities and Other Liabilities
Total other accrued liabilities
Other accrued liabilities
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]
Schedule of Future Minimum Lease Payments
Location, Statement of Income, Balance [Axis]
Description of Operations and Summary of Significant Accounting Policies
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]
Capitalized fees paid, net
Capitalized Contract Cost, Net
Capitalized Contract Cost, Net, Total
Retained Earnings [Member]
Retained Earnings (Accumulated Deficit)
Customer three.
Customer Three [Member]
Customer Three
Armata march two thousand twenty four term loan.
Armata March Two Thousand Twenty Four Term Loan [Member]
Armata March 2024 Term Loan
Nanolive
Nanolive [Member]
Nanolive [Member]
Accrued interest payable
Interest Payable, Current
Entity Registrant Name
Depreciation
Depreciation, Total
Denominator:
Denominator [Abstract]
No definition available.
Net income (loss)
Net income
Net income
Net loss
Net income (loss) and comprehensive income (loss)
Selling, General and Administrative Expense, Total
Selling, General and Administrative Expense
Selling, general and administrative
Thereafter
Lessee Operating Lease Liability Payments Due After Year Four
Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year.
Entity Address, Address Line One
UNITED STATES
United States
U.S.
Inventory, Raw Materials, Net of Reserves
Raw materials
Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]
Preferred stocks - Privately held healthcare company
Total current assets
Assets, Current
Current assets
Fair Value, Recurring and Nonrecurring [Table]
Deferred Royalty Obligation, Non Current
Long-term portion of deferred royalty obligation.
Long-term portion of deferred royalty obligation
Equity Securities Owned
Equity securities owned.
Number of shares owned
Long-term debt maturities for years ending December 31:
Long-Term Debt, Fiscal Year Maturity [Abstract]
Supplemental Cash Flow Information [Abstract]
Supplemental Disclosure of Cash Flow Information:
Common stock
Investments In Common Stock
Investments In Common Stock
Deferred income taxes
Deferred Income Tax Expense (Benefit)
Deferred Income Tax Expense (Benefit), Total
Entity Small Business
Long-Term Debt, Excluding Current Maturities
Long-term debt, net of discount and issuance costs
Total long-term debt, net
Total long-term debt, net
Consolidated Entities
CONSOLIDATED ENTITIES
Variable Interest Entity [Line Items]
In Process Research and Development [Member]
In-process research and development
IPR&D
Investment, Name [Domain]
Dilutive effect of options and awards granted under equity incentive plan and employee stock purchase plan
Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements
Incremental Common Shares Attributable to Share-based Payment Arrangements, Total
Amount of securities purchase agreement
Securities Purchase Agreement, Amount
The amount the Company agreed to pay for common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.
Two thousand twenty eight notes.
Two Thousand Twenty Eight Notes [Member]
2028 Notes
Remaining balance paid upon maturation
Debt Instrument Remaining Balance Paid upon Maturation
Debt instrument remaining balance paid upon maturation.
Long-Term Debt, Type [Axis]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Investments In Convertible Notes
Investments in convertible notes.
Amount of investment in convertible notes
Consolidation Items [Domain]
Accrued personnel-related expenses
Employee-related Liabilities, Current
Employee-related Liabilities, Current, Total
Publicly traded healthcare companies.
Publicly Traded Healthcare Companies [Member]
Publicly Held Healthcare Companies
Anti-Dilutive Securities
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Non Rule 10B51 Arr Modified Flag
Non Rule 10B51 Arr Modified Flag
Non Rule 10b51 Arrangement Modified
Earnings Per Share [Abstract]
Net income (loss) per share:
Manufacturing Stage Transfer Agreement [Member]
Manufacturing Stage Transfer Agreement
Manufacturing Stage Transfer Agreement
Royalty rate for first level of annual global net sales (as a percent)
Collaborative Arrangement, Royalty Rate Defined, Level One
Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales.
Increase (Decrease) in Payables Related to Purchase of Property and Equipment
Increase (decrease) in payables related to purchase of property and equipment.
Decrease in payables related to purchase of property and equipment
Increase (Decrease) in Carrying Amount of Investments
Increase (decrease) in carrying amount of investments.
Carrying amount of investments
Shares repurchased average price per share
Common Stock Acquired Average Cost Per Share
Common Stock Acquired Average Cost Per Share
Lessee, Operating Lease, Liability, to be Paid, Year Four
2030
Proceeds from Warrant Exercises
Proceeds from exercise of warrants
Plan Name [Axis]
Subsequent Event Type [Axis]
Principal amount of term loans owned
Principal Amount of Term Loans Owned
Principal amount of term loans owned.
Outstanding 2028 notes.
Outstanding 2028 Notes [Member]
Outstanding 2028 Notes
Equity [Abstract]
Products and Services [Domain]
Product and Service [Domain]
Stockholders' Equity
Equity [Text Block]
Measurement Frequency [Axis]
Cash flows from financing activities
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]
Future potential milestone payment receivable.
Future Potential Milestone Payment
Future potential milestone payment receivable
Obligation to pay development, regulatory and sales milestone payments as well as royalties
Other Sundry Liabilities, Noncurrent
Other
Intangible Asset, Indefinite-Lived, Class [Domain]
Consolidated Entities [Axis]
Interest Rate of Deferred Royalty Obligation
Interest rate of deferred royalty obligation.
Interest Rate of Deferred Royalty Obligation
Interest and Dividend Income, Operating
Interest and dividend income
Interest and dividend income
Interest and dividend income
Entity Tax Identification Number
Conversion of 2025 Notes to common stock, shares
Stock Issued During Period, Shares, Conversion of Convertible Securities
Treasury Stock, Common, Shares
Treasury stock, shares
Treasury stock balance (in shares)
Treasury stock balance (in shares)
Goodwill, impairment losses
Goodwill, Impairment Loss
Equity Component [Domain]
Equity Component [Domain]
Armata March 2025 Term Loan
Armata March Two Thousand Twenty Five Term Loan [Member]
Armata march two thousand twenty five term loan.
License And Other Revenue [Member]
License and other revenue member.
License and other revenue
Entity Address, City or Town
Accrued liabilities to provide for indemnifications and other contingencies
Accrued Liabilities Indemnifications And Other Contingencies
Accrued liabilities to provide for indemnifications and other contingencies.
Sales milestone payments receivable.
Sales Milestone Payments Receivable
Sales milestone payments receivable
Intangible Asset, Finite-Lived [Line Items]
Long-Term Debt, Maturity, Year One
2027
Cash paid for income taxes
Income Tax Paid, after Refund Received
Income Taxes Paid, Net, Total
United Kingdom
UNITED KINGDOM
Convertible senior notes
Senior Unsecured Convertible Notes [Member]
Borrowing which takes priority over other debt securities and can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.
Entity Common Stock, Shares Outstanding
Concentration Risk Type [Axis]
Increase (Decrease) in Long-Term Receivables, Current
Receivable from collaboration arrangement
Entity [Domain]
Entity [Domain]
Royalty financing agreement member.
Royalty Financing Agreement [Member]
Royalty Financing Agreement
Intangible Asset and Goodwill [Text Block]
Goodwill and Intangible Assets
Antidilutive Security, Excluded EPS Calculation [Table]
License revenue recognized
License Revenue Recognized
License revenue recognized.
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Shares used to compute net income (loss) per share:
Represents the royalty payable, as a percentage of net sales.
Percentage Of Royalty Payable On Net Sales
Percentage of royalty payable on net sales
Purchases of trading securities
Payments to Acquire Marketable Securities
Statement [Table]
Innoviva Strategic Opportunities, LLC
Innoviva Strategic Opportunities Limited Liability Corporation [Member]
Represents information pertaining to Innoviva Strategic Opportunities, LLC.
Deferred Revenue, Current, Total
Deferred Revenue, Current
Deferred revenue
Royalty revenue
Royalty [Member]
Royalty Revenue
Lease, Cost
Total lease costs
Total stock-based compensation expense
Share-Based Payment Arrangement, Expense
Stock based compensation expense
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Income (loss) before income taxes
Segment Reporting, Reconciliation of Profit (Loss) by Segment to Consolidated [Table Text Block]
Schedule of reconciliation to the consolidated net income
Entity Shell Company
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Net cash used in investing activities
Statement [Line Items]
Statement
Financial Instruments and Fair Value Measurements
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Measurements
Maximum [Member]
Maximum
Allowance for Expected Credit Losses
Allowance for expected credit losses.
Money market fund and cash.
Money Market Fund and Cash
Money market fund and cash
Debt Disclosure [Abstract]
Sale of Stock [Domain]
Investment Income, Interest
Investment income, interest
Payment upon maturity of debt instrument
Repayments of Unsecured Debt
Payment for repurchase of convertible subordinated notes due 2023
Payment for repurchase of convertible subordinated notes due 2023
Payment for repurchase of convertible subordinated notes due 2025
Future potential milestone payable
Future Potential Milestone Payable
Future potential milestone payable.
Concentration Risk Benchmark [Axis]
Two Thousand Twenty Six Equity Incentive Plan [Member]
Two thousand twenty six equity incentive plan.
2026 Equity Incentive Plan
Amortization of capitalized fees and depreciation of property and equipment
Amortization of Capitalized Fees and Depreciation of Property and Equipment
Amortization of capitalized fees and depreciation of property and equipment.
Asset Class [Axis]
Finite lived intangible asset expected amortization after year four.
Finite Lived Intangible Asset Expected Amortization After Year Four
Future amortization expense, thereafter
Treasury Stock Shares Acquired Including Accrued Excise Tax
Treasury stock shares acquired including accrued excise tax.
Repurchase of common stock, including accrued excise tax (in shares)
Repurchase of shares to satisfy tax withholding
Payment, Tax Withholding, Share-Based Payment Arrangement
Equity Investment
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Basilea
Basilea [Member]
Basilea.
Basilea [Member]
Investments
Total investments held by ISP Fund LP
Amortization of debt issuance costs
Amortization of Debt Issuance Costs
InCarda Convertible Notes
InCarda Convertible Notes [Member]
InCarda convertible notes.
Equity Method Investments [Policy Text Block]
Equity and Long-Term Investments
Other Noncurrent Liabilities [Table Text Block]
Schedule of Other Long-term Liabilities
Current assets:
Assets, Current [Abstract]
Lexington, Massachusetts
Lexington Massachusetts [Member]
Lexington Massachusetts.
ArmataTerm Loan
Armata Term Loan [Member]
Armata term loan.
GSK
G S K [Member]
Represents GSK, with whom the entity has agreements and arrangements, such as those for developing and commercializing different products.
Document Fiscal Year Focus
Common stock, shares outstanding
Balance (in shares)
Balance (in shares)
Common Stock, Shares, Outstanding
Balance
Total stockholders' equity
Balance
Equity, Including Portion Attributable to Noncontrolling Interest
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Number of major customers
Number Of Major Customers
Number of major customers.
Financial Instruments [Domain]
Financial Instruments [Domain]
La jolla pharmaceutical company member.
La Jolla Pharmaceutical Company [Member]
La Jolla Pharmaceutical Company
Summary of Liability and Equity Components of Convertible Notes
Convertible Debt [Table Text Block]
Net Income (loss) (in shares)
Profit Loss Shares
Profit Loss Shares
Intangible assets
Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Indefinite-Lived
Intangible assets pertain to product rights and developed technologies
Retirement of treasury stock (in shares)
Stock repurchased and retired during period, shares
Stock Repurchased and Retired During Period, Shares
Retirement of treasury stock (in Shares)
Operating Lease, Liability, Noncurrent
Long-term portion of lease liabilities
Operating Lease, Liability, Noncurrent, Total
Credit loss
Debt Securities, Available-for-Sale, Allowance for Credit Loss
Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance
Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance
Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total
Intangible Asset, Finite-Lived [Table Text Block]
Summary of Accumulated Amortization of Recognized Intangible Assets
Lessee, Operating Lease, Liability, to be Paid
Total
Total undiscounted lease payments
Additional Paid in Capital, Common Stock, Beginning Balance
Additional paid-in capital
Additional Paid in Capital, Common Stock
Additional Paid in Capital, Common Stock, Ending Balance
Security Exchange Name
Revenues, Total
Revenues
Related and Nonrelated Parties [Axis]
New Accounting Pronouncements, Policy [Policy Text Block]
Recently Issued Accounting Pronouncements Not Yet Adopted
Debt Instrument Transaction Cost
Debt instrument transaction cost
Debt instrument transaction cost
Warrants
Warrant [Member]
Description of Operations and Summary of Significant Accounting Policies
Summary of Significant Accounting Policies [Line Items]
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
Entity Address, State or Province
Accounts Receivable, after Allowance for Credit Loss, Total
Accounts Receivable, after Allowance for Credit Loss
Accounts receivable
Numerator:
Numerator [Abstract]
No definition available.
Right-of-use assets
Operating Lease, Right-of-Use Asset
Right-of-use assets
Amendment Flag
Stock-Based Compensation
Share-Based Payment Arrangement [Text Block]
NUZOLVENCE [Member]
NUZOLVENCE.
NUZOLVENCE
Concentration Risk, Percentage
Concentration Risk, Percentage
Capitalized Contract Cost, Amortization
Amortization of capitalized fees paid
Less: amortization of capitalized fees paid
Total interest and amortization expense
Interest Expense, Debt
Debt Instrument [Axis]
Other income, net
Other Nonoperating Income (Expense)
Other Nonoperating Income (Expense), Total
Other expense, net
Other expense, net
Contractual interest expense
Interest Expense, Debt, Excluding Amortization
Cash and cash equivalents at end of period
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
Total cash, cash equivalents and restricted cash at end of period shown in the condensed consolidated statements of cash flows
Cash and cash equivalents at beginning of period
XACDURO
XACDURO [Member]
XACDURO [Member]
Represents information pertaining to ImaginAb.
ImaginAb
Imaginab [Member]
Interest Expense, Borrowings [Abstract]
Interest expense
ANORO
Long Acting Beta2 Agonist Anoro [Member]
Represents Long-Acting Beta2 Agonist, ANORO, which is being developed and commercialized by entering into a strategic alliance with GSK
Variable Interest Entity [Table]
Summary of Significant Accounting Policies [Table]
Information related to various accounting policies of the entity.
City Area Code
Represents the royalty rate for combination products.
Royalty rate for combination products (as a percent)
Collaborative Arrangement Annual Royalties as Percentage of Net Sales for Combination Products
Preferred stock
Preferred Stock [Member]
Preferred Stock
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Proceeds from issuances of common stock, net
Proceeds from Issuance of Common Stock
Total capital contribution
Asset Acquisition [Abstract]
Operating Expenses [Abstract]
Operating expenses:
Operating expenses:
Unrealized Other Gain Loss on Investments
Unrealized other gain loss on investments
Changes in fair values of equity and long-term investments, net
Other Liabilities, Total
Other Liabilities
Other
Common stock, par value (in dollars per share)
Common Stock, Par or Stated Value Per Share
Legal Entity [Axis]
Reimbursements for Research and Development Expense
Reimbursements for research and development expense.
Research and development expense
Short-Term Debt, Type [Domain]
Current liabilities
Total current liabilities
Liabilities, Current
Noncash Investing and Financing Items [Abstract]
Supplemental Disclosure of Non-cash Investing Activities:
Consolidated Entities
No definition available.
Two thousand twenty three notes.
Two Thousand Twenty Three Notes [Member]
2023 Notes
Variable Lease, Cost
Variable lease costs
Segment Reporting
Segment Reporting [Text Block]
Debt Securities, Available-for-Sale [Table Text Block]
Schedule of Amortized Cost and Estimated Fair Values for Available-for-Sale Securities
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Royalties payable period after first commercial sale of product.
Royalties Payable Period After First Commercial Sale Of Product
Royalties payable period after first commercial sale of product
Trading Symbol
Geographical [Axis]
Amortization of debt discount and issuance costs
Amortization of Debt Issuance Costs and Discounts
Amortization of Debt Issuance Costs and Discounts, Total
Fair value of assets or liabilities transfer between levels
Fair Value Of Assets Or Liabilities Transfer Between Levels
Fair Value Of Assets Or Liabilities Transfer Between Levels
Repurchase of common stock, including accrued excise tax
Treasury Stock Value Acquired Cost Method Including Accrued Excise Tax
Treasury stock value acquired cost method including accrued excise tax.
Repurchase of common stock including accrued excise tax
Entity Emerging Growth Company
Additional Paid-In Capital
Additional Paid-in Capital [Member]
Purchases of equity investments managed by ISP Fund LP
Purchases of Equity Investments Managed by Isp Fund Lp
Purchases of Equity Investments Managed by Isp Fund Lp
Exercise of stock options and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding (in shares)
Exercise of stock options and issuance of common stock units, stock awards and purchase plan, net of cancellation of stock awards and repurchase of shares for tax withholding (in shares)
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Total
Total
Long-Term Debt, Gross
Principal amount
Outstanding balance
Plan Name [Domain]
Other Liabilities, Noncurrent
Other long-term liabilities
Total other accrued liabilities
Total other long-term liabilities
Accrued Income Taxes, Noncurrent
Income tax payable, long-term
Common and preferred stock
Common and Preferred Stock [Member]
Common and preferred stock member.
Innoviva's Common Stock
Innoviva's Common Stock Member
Commitments for 2024 to be utilized in 2025 [Member]
Commitments for 2024 to be utilized in 2025.
Commitments for 2024 to be utilized in 2025 [Member]
Amount on net product sales recognized
Amount on net product sales recognized.
Amount on Net Product Sales Recognized
Customer one.
Customer One [Member]
Customer One
Cover [Abstract]
Operating Lease, Weighted Average Remaining Lease Term
Operating lease, Weighted average remaining lease term
Revenue from Contract with Customer [Abstract]
Revenue:
Long-term Debt, Type [Domain]
Long-Term Debt, Type [Domain]
Amount Of Investments In Common And Preferred Stock
Amount of investments in common and preferred stock
Amount of investment in common and preferred stock
Two thousand twenty five notes.
Two Thousand Twenty Five Notes [Member]
2025 Notes
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Concentrations of Credit Risk and of Significant Suppliers and Partner
External Services [Member]
External Services.
External Services and Expenses
Amortization of acquired intangible assets
Amortization of Intangible Assets, Total
Amortization expense
Schedule Of Financial Information Of Variable Interest Entities [Table Text Block]
Schedule of financial information of variable interest entities.
Schedule of Income Statements of VIE
Stock-based compensation
Share-Based Payment Arrangement, Noncash Expense
Share-based Payment Arrangement, Noncash Expense, Total
InCarda
Incarda [Member]
Represents information pertaining to InCarda.
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]
Adjustments to reconcile net income to net cash provided by operating activities:
Armata August 2025 Term Loan
Armata August Two Thousand Twenty Five Term Loan [Member]
Armata august two thousand twenty five term loan.
Fair Value Disclosures [Abstract]
Cash and Cash Equivalent
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value, Total
Cash and Cash Equivalents, at Carrying Value, Beginning Balance
Cash and Cash Equivalents, at Carrying Value, Ending Balance
Retirement of treasury stock
Stock repurchased and retired during period, value
Stock Repurchased and Retired During Period, Value
Retirement of treasury stock
Equity investment
Equity Securities [Member]
Amount of shares repurchased
Share Repurchase Program, Remaining Authorized, Amount
Accrued Excise Tax On Common Stock Repurchase Applied Against Tax Liability1
Accrued excise tax on common stock repurchase applied against tax liability.
Accrued excise tax on common stock repurchase applied against tax liability
George Washington University.
George Washington University [Member]
George Washington University
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Net cash provided by (used in) financing activities
Trade Accounts Receivable [Member]
Receivables from Net Product Sales
Clinical development and regulatory milestones amount payable.
Clinical Development And Regulatory Milestones Amount Payable
Clinical development and regulatory milestones amount payable
Armata july two thousand twenty three term loan.
Armata July Two Thousand Twenty Three Term Loan [Member]
Armata July 2023 Term Loan
Nonrecurring basis
Fair Value, Nonrecurring [Member]
Net loss attributable to Innoviva stockholders
Net Income (Loss) Available to Common Stockholders, Basic
Net income attributable to Innoviva stockholders
Net income (loss), basic
One-time Milestone Payment on Net Sales
Subscription agreement one-time milestone payment on net sales.
Subscription Agreement One-time Milestone Payment on Net Sales
Term of milestone payment for commercial sale.
Term of Milestone Payment for Commercial Sale
Term of milestone payment for commercial sale
Entity Filer Category
Debt Instrument, Name [Domain]
Debt Instrument, Name [Domain]
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description
Lease Contractual Term [Axis]
Increase (Decrease) in Accounts Receivable
Accounts receivable
Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year One
Future amortization expense, 2027
Amortization of fair value adjustments of cost of products sold.
Amortization of Fair Value Adjustments of Cost of Products Sold
Amortization of fair value adjustments of Cost of products sold
Total property and equipment, net
Property and equipment, net
Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization
Property, Plant and Equipment, Net, Beginning Balance
Property, Plant and Equipment, Net, Ending Balance
Maximum aggregate royalty payments due.
Maximum Aggregate Royalty Payments Due
Maximum aggregate royalty payments
Cost Reimbursement
Cost Reimbursement [Member]
Cost reimbursement.
Revenue from Contract with Customer, Excluding Assessed Tax
Total revenue
Total net royalty revenue
Total royalty revenue
Inventory Disclosure [Abstract]
Asset Acquisition [Domain]
Loan, Held-in-Portfolio, Principal Outstanding
Loan, Held-in-Portfolio, Principal Outstanding, Total
Outstanding principal
Segment Reporting [Abstract]
Zai Lab.
Zai Lab [Member]
Zai Lab
Other Assets, Current
Other current assets
Entity Address, Postal Zip Code
Harvard University.
Harvard University [Member]
Harvard University
Statement of Financial Position [Abstract]
Local Phone Number